VolitionRx initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Yi Chen initiated coverage of VolitionRx (VNRX) with a Buy rating and $2.50 price target VolitionRx is a diagnostics company focused on the development of epigenetic tests based on nucleosomes that can enable early detection of diseases including certain cancers and sepsis, the analyst tells investors in a research note. The firm says the company’s Nu.Q diagnostic technology is validated by the commercialized Nu.Q Vet cancer test.